Pane wikiwiki
A purity percentage is one axis, not a characterization. What to demand on a CoA: ʻikena orthogonal, HPLC method detail, nā ʻāpana endotoxin, lot traceabilit
ʻOiaʻiʻo ka Momentum, aka, kau ia ma ke kumu hookahi

Ke piʻi maoli nei ka noi BPC-157, a ʻoi aku ka lahilahi o nā hōʻike no kēlā piʻi ʻana ma mua o nā poʻomanaʻo. A 2025 loiloi ʻōnaehana ma HSS Journal Ua loaʻa iā BPC-157 Google ka nui o ka huli ʻana i kahi kiʻekiʻe i ka mahina o Iune 2024, me ka oi aku 50 miliona mau manaʻo wikiō BPC-157-tag ma YouTube a me TikTok a ʻoi aku 100,000 nā lālā i nā kaiāulu Reddit pili i ka peptide. He hōʻailona maoli kēlā, a he kumu hoʻokahi nō i uka: ʻO ka hapa nui o nā ʻatikala "BPC-157 e pahū ana" i paʻi ʻia mai ka huli ʻana i kēia loiloi hoʻokahi.
ʻOi aku ka palupalu o ka ʻaoʻao lapaʻau. Ua hōʻike ʻo Reuters i kahi paʻi mua nference i ʻike ʻia 1,039 nā poʻe maʻi ma mua o 15 miliona mooolelo, me ka piʻi ʻana o 33 mau mea hoʻohana i hoʻopaʻa ʻia ma waena 2020 a 2026. ʻAʻole i nānā ʻia kēlā preprint, ʻO ka mea nui i ka wā e hana ai kahi ʻikepili i nānā ʻole ʻia i kēia hana nui i ke kamaʻilio.
Ki Takeaway: ʻO nā koi Momentum e pili ana i ka BPC-157 he kani-kaumaha. Ma mua o ka hana hou ʻana i kahi helu ulu, e inoa i ka haʻawina ma hope o ia mea a inā ua hoʻomaʻemaʻe ia i ka loiloi hoa.
ʻAʻohe o kēia e hoʻopunipuni i ka manawa. Hoʻolilo ia i ka nīnau pili i ka mea mua a ka mea heluhelu makaʻala e nīnau ai, a hoʻonohonoho i ka pilikia paʻakikī: Ke lawelawe ʻia nei kahi waihona mea hoʻohana e piʻi aʻe nei e nā huahana nona nā koi o ka maikaʻi ma luna o kahi helu i ʻōlelo ʻia ʻoi aku ka liʻiliʻi ma mua o ka mea i ʻike ʻia. ʻO kēlā āpau kahi e hoʻomaka ai ka hōʻailona BPC-157.
Ka Nānā Kuʻuna: ʻO ka Maʻemaʻe ka moʻolelo holoʻokoʻa
He maʻalahi ke kūlana koʻikoʻi: he chromatography wai hana kiʻekiʻe (HPLC) kiʻi maʻemaʻe ma kahi palapala hōʻoia (KoA) lawa ka hōʻike ʻana he peptide ka pae noiʻi. Ma kēlā loina, 99% ʻo ia ka laina hoʻopau, a me kekahi mea maluna 98% hiki ke hoololi.
He mea maʻalahi ke ʻike i ke kumu i paʻa ai kēia pōkole. He helu hookahi ka maemae, hoʻohālikelike i nā mea hoʻolako, hiki ke paʻi ʻia ma ka ʻaoʻao huahana, a hiki ke heluhelu ʻia i ka mea kūʻai aku nona kanakolu kekona e hoʻoholo ai. Hoʻopili ia i kahi manaʻo analytical kūpono i loko o kahi ʻāpana kūʻai.
Hoʻopili paʻa nā kiʻi i hoʻopuka ʻia e ka mea kūʻai aku ma luna o kēlā unahi. ʻO nā mea hoʻomaʻemaʻe i helu ʻia no ka BPC-157 98.329%, 99.41%, 99.54%, 99.55%, 99.74%, 99.8%, a 99.86%, a ua hōʻike kekahi mea hōʻuluʻulu i ke ʻano o 99.52% ma kela aoao 18 nā ho'āʻo me ka laulā o 99.02% i 99.90%. Hōʻike ʻia kēia mau helu iā lākou iho a me ka mālama ʻole ʻia, no laila e mālama iā lākou ma ke ʻano he hōʻailona o kahi kumu kūʻai ma mua o ka helu mākeke.
No ke kōkua: E heluhelu i ka helu maʻemaʻe ma ke ʻano he koi e pili ana i ka nui, ʻaʻole he waiwai o ka mole. He helu me ke ala ʻole, he kolamu, a ʻo ka lōʻihi nalu ʻike he hōʻuluʻulu o ka hopena o kekahi, ʻaʻole ka hōʻike ma hope.
ʻO ka ʻokoʻa he CoA piha. Hoʻopili ka mea koʻikoʻi i ka nui hoʻokahi i nā hopena lab i kapa ʻia a hōʻike i nā ʻano me nā waiwai: ʻike ʻia e ka mass spectrometry e kūʻē i ka theoretical mass, HPLC maemae me ke kolamu, gradient ʻāpana paʻalima a me ka lōʻihi hawewe ʻike (maʻa mau 214 nm), ʻaoʻao haumia, ʻano kūʻē a paʻakai paha, ka mākū a i ʻole ka ʻupena peptide maʻiʻo, he hopena endotoxin helu me nā ʻāpana a me ka hoʻāʻo, sterility kahi i koi ʻia, me ka helu hailona, lā hoʻāʻo, hale hoʻokolohua, hōʻailona hōʻailona a me ka mana (pehea e heluhelu ai i kahi peptide CoA, 2026-05-24). ʻO ia ke kūlana palapala e hoʻoholo ai i kahi palapala helu helu hoʻokahi, a ma laila ka hoʻomaka ʻana o ka ʻike kuʻuna.
No ke aha i hāʻule ʻole ai ka maʻemaʻe wale ma ke ʻano he BPC-157

ʻO ka pākēneka maʻemaʻe e pane pololei i hoʻokahi nīnau: ʻo ka nui o nā mea i ʻike ʻia e ka mea ʻike ma kahi lōʻihi nalu, ʻo ia ka piko nui. ʻAʻole ia e haʻi iā ʻoe inā he BPC-157 ka mole, pehea i hana ʻia ai, he aha ke kuʻekuʻe e lawe ai, a i ʻole nā mea ʻē aʻe i loko o ka hue. ʻO ka hōʻailona BPC-157 kahi pilikia multi-axis, a ʻo ka maʻemaʻe ka axis maʻalahi loa.
ʻO ka ʻike ʻo ia ka lua mua. ʻO ka hoʻāʻo kūʻokoʻa kūʻokoʻa a WIRED o nā hue peptide kūʻai kūʻai i ʻike ʻia nā huahana i hoʻohālikelike ʻia "ʻaʻole i loaʻa nā mea hana ma kā lākou mau lepili., ka BPC-157, ʻo kahi laʻana, ʻaʻohe BPC-157 i loko,” a ʻaʻole hiki ke ʻike maikaʻi ʻia kahi pūʻulu lua i kālai ʻia e Analytical Formulations (WIRED, Kepakemapa 2026). A 99% ʻO ke kiʻi ma kahi hue i paʻa ʻole ka BPC-157 ʻaʻole ia he hōʻailona maikaʻi. He ana ia o ka mea hewa.
ʻO ka ʻokoʻa o ke ala ka lua. ʻO ka maʻemaʻe e pili ana i ke ʻano: hiki ke hoʻololi i ka laʻana like ma kahi pākēneka a ʻoi aku paha me nā hoʻololi i ke kolamu, nā hoʻonohonoho gradient a me ka ʻike, no laila ʻaʻole hiki ke hoʻohālikelike ʻia kahi kiʻi me ka ʻole o nā kūlana HPLC ma waena o nā mea kūʻai aku a i ʻole nā hui (ChemVerify, 2026-06-14). Hōʻike ka helu pale i ke kolamu, ʻo ka gradient o ka manawa paʻalima a me ka lōʻihi hawewe ʻike, maʻa mau 214 nm. ʻO ka hapa nui o nā palapala hōʻoia e kāpae i nā mea ʻekolu.
ʻO ke kolu o ka ʻāwaha he haumia. Ua ʻike ʻia ka loiloi mākeke hina nui i paʻi ʻia a hiki i kēia lā 41.6% o nā laʻana i hāʻule i kahi hōʻailona hoʻohuihui lāʻau lapaʻau palupalu a 71.1% ʻaʻole i loaʻa kahi hōʻailona lāʻau i hana ʻia, oiai ma ke ano 2.4% ʻaʻole i loaʻa kekahi o ka peptide i kapa ʻia a 15% ʻO ka ʻāpana i hoʻāʻo ʻia e endotoxin i hōʻike i ka endotoxin bacteria hiki ke ana (Finnrick, 2026). ʻO ka hoʻāʻo ʻana i ka endotoxin peptide ke ala wale nō e ʻike ai i kēlā ʻano hana hemahema hope loa; ʻAʻole loa e loaʻa kahi chromatogram maʻemaʻe.
⚠️ ʻŌlelo Aʻo: Hōʻike like ʻole ka loiloi Finnrick i kāna helu laʻana ma nā ʻāpana, 6,441 ma kahi hookahi a 6,285 i kekahi. ʻAʻole i hoʻoholo ʻia ka ʻokoʻa, no laila e mālama i nā pākēneka ma ke ʻano he kuhikuhi ma mua o ka pololei.
Hookahi axis ka maemae. ʻIkepili, ʻO ke ala ʻokoʻa a me ka haumia nā mea ʻē aʻe, ʻaʻole hiki i ka helu hoʻokahi ke lawe.
He aha ka ʻikepili i hōʻike maoli ʻia e pili ana i ka BPC-157 Characterization

Hoʻopili hou ʻia i ka mea a nā regulators e noi maoli ai, Hoʻopau ka hōʻailona BPC-157 i ka hoʻokūkū maʻemaʻe a lilo i pilikia hōʻoia. ʻO ke alakaʻi alakaʻi EMA ma nā peptides synthetic, pono o Iune 2026, manaʻo ʻo ia "ʻelua mau ala orthogonal ... no ka ʻike" a loiloi i ka maʻemaʻe ma waena o ka nui-, uku- a me ka hoʻokaʻawale ʻana i ka hydrophobicity, a ʻōlelo maopopo ʻaʻole pili ʻo ICH Q3A i nā peptides synthetic. Hōʻoiaʻiʻo Orthogonal, ʻaʻole he helu poʻomanaʻo, ʻo ia ke koi.
ʻO ka ʻike ponoʻī he waihona, ʻaʻole hoʻokahi hoʻāʻo: intact mass me ka peptide-mapping sequence coverage, ka nānā ʻana i ka waikawa amino no ka haku mele ʻana, a me ka hoʻonā chromatographic o nā ʻano like ʻole pili pili, me ka papa hana kiʻekiʻe i nānā ʻia e ka circular dichroism a me DSC inā pili, me ke aupuni oligomeric. E hahai ana ka Endotoxin i ka loina like. ʻO ka USP 〈85〉 endotoxin-limit framework ʻike i ʻekolu mau ʻano hana LAL i hoʻopaʻa ʻia, me ka ʻike gel-clot maʻamau o 0.03–0.25 EU/mL a me nā pae turbidimetric a i ʻole chromogenic o 0.001–100 EU/mL, a kau i nā palena mai K/M, kahi o K 5.0 EU / kg no ka intravenous a 0.2 EU / kg no nā huahana intrathecal.
|
Axis |
Nīnau ia pane |
ʻO nā hōʻike e pane ai |
Hāʻule ka hopu ʻana |
|---|---|---|---|
|
ʻIkepili |
ʻO kēia ka molekala kūpono? |
Nuipa paʻa, palapala palapala peptide, ka nānā ʻana i ka ʻakika amino |
Nā ʻano like ʻole a me nā pani |
|
ʻO ka maʻemaʻe me ke ʻano alohilohi |
Pehea ka nui o ka peptide target? |
Hoʻokaʻawale Orthogonal i ka nui, uku, hydrophobicity |
He helu hoʻokahi e hūnā ana i nā mea haumia |
|
ʻO ka haumia a me ka ʻaoʻao counterion |
He aha hou aʻe? |
Ho'āʻo pili-mea a me counterion |
Nā mea hoʻoheheʻe koena, TFA, nā kaʻina i ʻoki ʻia |
|
Hoʻohuihui Peptide Endotoxin |
He palekana no ke ala i manaoia? |
ʻO ke ala LAL i hōʻoia ʻia ʻO nā Peptides Synthetic kū'ē i nā palena K/M |
ʻO ka hoʻolaha ʻana i ka endotoxin pili i ke ala |
|
Ka palapala a me ka hiki ke huli |
Hiki ke nānā ʻia kekahi o kēia? |
Palapala hōʻoia, ʻano kikoʻī, pūʻulu moʻolelo |
ʻAʻole hiki ke hana hou ʻia nā koi |
ʻO kēia hiʻohiʻona ʻelima-axis he synthesis o nā kūlana i paʻi ʻia, ʻaʻole he koi hou. Hoʻonohonoho wale ia i nā mea i koi ʻia e nā palapala EMA a me USP i nā nīnau e nīnau ai ka mea kūʻai aku ma mua o ka ʻae ʻana i kahi kiʻi maʻemaʻe..
ʻO nā ʻAha ʻepekema ka moʻolelo maoli
ʻO ka bottleneck no ka BPC-157 ʻaʻole ia he kumu olaola. ʻO ka nele o ka ʻepekema hoʻokumu kumu, pharmacokinetics i hōʻoia ʻia, a me ka hoʻokolo ʻana i nā hoʻokolohua pono kanaka, ʻo ia ke ʻano o ka 2026 lāʻau lapaʻau hoʻolālā ka loiloi i ke kahua (Mateescu et al., lāʻau lapaʻau 18(5):625, kiʻi ʻia 2026-05-20). Ua helu ʻia ka loiloi like i ka waihona hōʻike kanaka i paʻi ʻia ma ke ʻano he ʻekolu mau haʻawina hoʻokele hoʻokele ʻole me ka hoʻopaʻa inoa ʻana ma lalo 30 nā kumuhana: he moʻo ʻeha kuli o 16 nā maʻi, owai 12 loaʻa i ka BPC-157 intra-articular wale nō; he hoʻokele cystitis interstitial o 12 wahine; a me kahi pailaka palekana intravenous o 2 kanaka makua olakino.
He kiko'ī ka mea i nalowale. ʻAʻohe ʻano hana i hoʻopaʻa ʻia i ka lāʻau lapaʻau, ʻaʻohe hiʻohiʻona permeability maʻamau a i ʻole ka helu BCS, ʻaʻohe haʻawina e pili ana i ka excipient-compatibility, ka hoʻonā ʻole ʻia a me ka paʻa o ka mālama ʻana, pharmacokinetics kanaka undercharacterized, ʻaʻohe ʻano hana bioanalytical kanaka i hōʻoia ʻia. ʻAʻole ʻike ʻia ka bioavailability waha, ʻAʻole ʻae ʻia nā pharmacokinetics subcutaneous, ʻAʻole paʻi ʻia ka hoʻopaʻa ʻana i ka protein plasma, a ʻaʻole i ana ʻia ka nui o ka puʻunaue.
Hoʻokahi Phase i hoʻopaʻa inoa 2 hoʻokaʻawale, makapō ʻelua, ka hoʻāʻo ʻana i ka hamstring-strain hoʻāʻo placebo (NCT07437547) nā pahu hopu 120 nā mea komo a ke hoʻopaʻa inoa nei. ʻAʻole i hōʻike i nā hopena, no laila ʻaʻole i pau ka Phase 2 hōʻike.
Aia nō ke kiʻi bibliometric i kāu helu ʻana. Hoʻi ka huli hoʻokahi 227 BPC-157 puke me 53 moolelo pili kanaka; hoi mai kekahi 232 pepa me 54 hōʻailona kanaka (PeptideDeck, Nā helu helu BPC-157, 2026). ʻO ka ʻokoʻa ka laulā nīnau, ʻo ia ke kumu e pono ai ka helu ʻana o ka hoʻolaha ʻana i kāna string hulina.
ʻO kēia mau āpau ka hoʻopaʻapaʻa no ka BPC-157 characterization discipline: i ka wā ʻaʻole hiki i nā palapala lapaʻau ke haʻi iā ʻoe i ka hana o kahi hoʻomākaukau i loko o ke kanaka, ʻoi aku ka kaumaha o ka palapala o ka mea i loko o ka hue, aole emi. Hana ʻia ʻo Peptide
ʻAʻole i hoʻoholo ʻia ke kiʻi hoʻoponopono, ʻAʻole i hoʻopaʻa ʻia
Nā lawelawe ʻO Iulai 2026 ua hoʻololi ka ʻōlelo aʻoaʻo i ke kamaʻilio ʻana, ʻaʻole ke kānāwai. Ma ka 2026-07-23, ua koho ke komite aʻoaʻo hui lāʻau lapaʻau 8 i ke aloha, 6 kūʻē, me 1 haʻalele, e paipai i ka waihona manuahi a me ka acetate BPC-157 no ka papa inoa nui o ka Paukū 503A, ʻoiai ʻo nā mea hoʻopuka pōkole o nā limahana FDA i manaʻo i ka hopena ʻē aʻe, e like me McDermott Will & Heluhelu ʻo Emery i ke kaʻina hana 503A bulks-list mooolelo. Mai ka mahina o Kepakemapa 2026, ʻaʻohe hana FDA hope i hahai, a ʻo ka balota wale nō ʻaʻole ia e hoʻohui pono i ka BPC-157: ʻO ka hoʻokomo ʻana i ka bulks-list a me ka hoʻolaha ʻana a me ka manaʻo rulemaking.
He mea ʻokoʻa kēlā ʻokoʻa e nā mea kuleana. Pono nā mea noiʻi e mālama i kekahi mea hoʻolako e hōʻike ana i ke koho balota ʻana i ka BPC-157 me ke kuhi hewa ʻana i ke kūlana. Pono nā hui kūʻai a me QC e mālama i nā kūlana palapala peptide noiʻi i pili i ka mea i hōʻoia ʻia i kēia lā., ʻaʻole i kahi lula e kali nei. Kūlike nā mea kūʻai aku i ka ʻokoʻa ma waena o ka manaʻo a me ke kūlana kānāwai. Nā mea hoʻoponopono, i kēia manawa, ʻaʻole i hoʻoholo iki i ka nīnau.
ʻO ke kūlana ponoʻī o FDA he blunter mau. ʻAʻole ʻae ʻia ʻo BPC-157 i ka FDA no kekahi hōʻailona, ʻaʻohe lāʻau lapaʻau i ʻāpono ʻia. ʻO ka ʻaoʻao pilikia palekana o ke keʻena e waiho ana i ka BPC-157 i waena o nā lāʻau lapaʻau nui i hoʻihoʻi ʻia nā koho., e hōʻike ana i nā lāʻau i hoʻohui ʻia i loko o ia mea hiki ke hoʻopilikia i ka immunogenicity no kekahi mau ala o ka hoʻokele a loaʻa paha nā paʻakikī e pili ana i nā haumia pili i ka peptide a me ke ʻano API., a ua ʻike ʻo FDA ʻaʻole, a i ʻole i kaupalena ʻia, ʻike pili i ka palekana no nā ala i manaʻo ʻia o ka hoʻokele (FDA, ʻike i kēia manawa 2026-04-22).
Pehea e kau ai i keia: He Papa Hoike Hoike

E noi i ke ʻano, ʻaʻole ka helu. ʻO kēlā noi hoʻokahi ke ala wikiwiki loa e hoʻokaʻawale i kahi mea hoʻolako i hoʻomaopopo noiʻi peptide palapala kūlana mai ka mea e hana hou ana i kahi kiʻi kūʻai, a ke kumu kūʻai nei ʻoe i hoʻokahi leka uila.
-
Noi i ka CoA kiko'ī hailona. E hōʻoia i ka palapala hōʻoia no ka noiʻi peptides inoa i ka helu hailona, ke keʻena hoʻokolohua, a me ka lā hoʻāʻo. ʻAʻole hiki ke hoʻopaʻa ʻia kahi palapala i haʻalele i kekahi o nā mea ʻekolu i ka mea i mua ou.
-
E nānā inā he orthogonal ka hōʻike ʻike. ʻO kahi kiʻekiʻe HPLC hoʻokahi ʻenehana e pane i hoʻokahi nīnau. ʻOi aku ka ikaika o ka ʻike inā kekona, ʻae ke ʻano kūʻokoʻa.
-
E koi i nā ʻāpana ala HPLC. kolamu, gradient, a ʻo ka lōʻihi hawewe ʻike pili i ka waiwai maʻemaʻe. Me ka ʻole o lākou, ʻaʻole hiki ke hana hou ʻia ka pākēneka.
-
E koi i ka hopena endotoxin helu me nā ʻāpana a me ka hoʻāʻo. ʻO ka hoʻāʻo ʻana o ka peptide endotoxin pono e hōʻike i ka EU/mL no ka hoʻonā ʻana ma kahi ʻano hana i wehewehe ʻia, a i ʻole EU/mg i ka wā maʻamau i ka peptide mass, a pono e kākau i ka mana huahana maikaʻi me ka hoʻihoʻi spike (ʻae pinepine ʻia a puni 50 i 200%) me ka hoʻoheheʻe ʻia ʻana o ka mana kūpono, no ka mea hiki i nā peptides ke kāohi a hoʻonui i ka hōʻailona LAL (Alakaʻi hoʻāʻo ʻo Assyro endotoxin, kiʻi ʻia 2026-09-14).
-
E hōʻoia i ka counterion a i ʻole ke ʻano paʻakai, ka mākū a i ʻole ka ʻupena peptide maʻiʻo, a me ka hiki ʻana o ka puʻupuʻu. TFA a me hale kūʻai ʻokoʻa ke ʻano o nā paʻakai acetate, a hoʻololi ka ʻike peptide net pehea ʻoe e helu ai i ka ʻike hana.
Hoʻokahi koho ma waena o kekahi: he mea hoolako e hana ana i ka Papa 100 lumi maʻemaʻe me ka HPLC hale, MS, a me ka sterility QC hiki ke hoʻohana ʻia e hōʻuluʻulu i kahi pūʻolo kikoʻī kikoʻī ma ka milligram a hiki i ka paona kilo., e kākoʻo ana i kahi noi palapala ma mua o ka hoʻololi ʻana.
E ana i ka pane, aole ka olelo hoopomaikai. ʻO kahi mea hoʻolako e pane i nā nīnau ʻano e haʻi iā ʻoe i kekahi mea; ʻO ka mea huli i ke kiʻi maʻemaʻe ke haʻi hou aku iā ʻoe. E kali i ka pane palapala i loko o nā lā. ʻOi aku ka lōʻihi o kahi hopena noiʻi.
Hōʻike: Kahi o kēia hoʻopaʻapaʻa nawaliwali loa
ʻAʻole hiki i kahi pūʻolo kikoʻī koʻikoʻi ke hana i kahi ʻae ʻole ʻia, palekana a maikaʻi paha ka peptide i aʻo ʻia, a ʻo ka palapala ʻoi aku ka maikaʻi ʻaʻole ia he pani no nā hōʻike lapaʻau. ʻAʻohe mea ma ʻaneʻi e hoʻololi i kēlā.
ʻO ka papa hana ʻelima-axis he synthesis o nā kūlana i paʻi ʻia, ʻaʻole hoʻokahi protocol citable. He hōʻuluʻulu manaʻo ko ka EMA, a ʻo ke kumu ponoʻī e ʻōlelo pono e hoʻopaʻa ʻia nā paepae pākēneka e kūʻē i ka kikokikona mua. ʻAʻole kūlike ka helu hoʻohālikelike Finnrick ma waena o nā hōʻuluʻulu. No ka paʻi paʻi mua ʻana o ka helu hoʻohana hoʻonui, a ʻo nā helu PubMed e pili ana i ka nīnau.
Hiki ke pale ʻia ka ʻike maʻemaʻe-mua ma kahi ʻē aʻe. No kahi hiʻohiʻona maikaʻi, peptide i ʻae ʻia me kahi monograph i hōʻoia ʻia, ʻoi aku ka nui o ke kaumaha ma mua o kēia, no ka mea, ike, ʻaoʻao haumia, a ua hoʻopaʻa ʻia nā palena endotoxin e ka monograph.
ʻO ka hoʻopaʻapaʻa he pono ke ʻano o ka BPC-157, ʻaʻole lawa.
Akā ʻaʻole i haʻi mai ka helu maʻemaʻe kiʻekiʻe iaʻu i kekahi mea?
Ke hana nei, akā, i hui pū ʻia me ʻelua ʻāpana ʻike: ke ʻano i hana ai i ke kiʻi a me ka hōʻike ʻike e hōʻoia ana i ke ʻano o ka piko. A 99.8% ʻAʻole like ka hoʻopiʻi ʻana mai ka holo ʻana o ka HPLC o hoʻokahi lab me a 99.8% hopena mai kekahi, no ka mea, pili ka helu i ka gradient, ka lōʻihi nalu ʻike, a me ka piko maʻamau ma hope. Me ka ʻole o ke ʻano, he ana ke kii i kekahi mea, ʻaʻole pono o BPC-157.
Inā ua kūʻai mua ʻoe i nā hue ma ka ikaika o kahi kiʻi maʻemaʻe, ʻO ka hoʻolei ʻana iā lākou ma ka manaʻo ʻaʻole wale ke koho. E noi i ka palapala kumu kumu mai ka mea hoʻolako a, kahi e pili ai ka mea i kāu hana, komisina kūʻokoʻa kūʻokoʻa a me ka hoʻāʻo endotoxin. ʻO ia ka mea e hoʻololi i kahi koi i hōʻoia ʻole ʻia i palapala, a emi loa ke kumu kūʻai ma mua o ka hoʻomaka hou ʻana i kahi haʻawina.
Pono ke kamaʻilio pololei ʻana i ka balota PCAC, no ka mea, heluhelu pinepine ia me he kukui omaomao. He koho aʻoaʻo, ua maheleia, a me nā limahana FDA e kū'ē i ka hoʻokomo. ʻAʻohe kānāwai hope i hahai ʻia. ʻO ka ʻokoʻa ma waena o ka ʻōlelo aʻoaʻo kōmike a me ke kūlana kānāwai ke kumu holoʻokoʻa.
Ma ka endotoxin, ʻO ka mea maʻamau, ʻoi aku ka nui o ka hana hoʻokolohua. Aia paha ia ma ke ala a me ka nui, a ua hoʻonohonoho ʻia ka palena e pili ana i kēlā mau ʻano ʻelua ma mua o ka hoʻonohonoho. ʻO ke kumu i nīnau ʻia ai ka nīnau 15% ʻO ka ʻāpana i hoʻopaʻa ʻia i hōʻike i ka endotoxin hiki ke ana. ʻAʻole ia he kumu e hoʻāʻo ai i nā mea āpau me ka ʻole; he kumu ia e ʻike ai i ka nīnau āu e pane nei ma mua o kou hoʻoholo ʻana ʻaʻole pono ʻoe e nīnau. E pili ana
Ka hopena: Pono e wehewehe i ke ano o ka noiʻi-papa BPC-157
ʻO ka pōkole maʻemaʻe-mua he hui kūʻai, ʻaʻole kahi maʻamau analytical, a hoʻomaka ka hōʻailona BPC-157 ma kahi e pau ai kēlā pōkole: hōʻoia ʻike orthogonal, ʻano-māmā ʻaʻa, haumia a me ka counterion profiling, hōʻike helu endotoxin, a me nā palapala kikoʻī i hiki i ka mea loiloi ke hoʻoponopono.
Ua ʻike ʻia ka neʻe ʻana o kēia manaʻo hoʻopaʻapaʻa i ka hana ʻana o nā hui kūʻai ikaika loa. Nīnau lākou i nā nīnau ma mua o nā nīnau kumu kūʻai. Hana lākou i kahi palapala hōʻoia no ka peptides noiʻi ma ke ʻano he palapala hoʻomaka ma mua o kahi pani, a manaʻo lākou e hoʻopuka nā mea hoʻolako i nā gradients, kolamu, a me nā lōʻihi nalu ʻike ma kahi o ka pākēneka hoʻokahi. I ka laha ana o kela manao, ʻO nā kūlana palapala peptide noiʻi e pau i ka hoʻokō ʻana ma hope o ka noʻonoʻo ʻana a lilo i huaʻōlelo o ke kamaʻilio kūʻai ʻana iho..
E kiʻi i ka mākeke e pili ana: a 99% kiʻi me ka helu ʻole ʻana o ka gradient i ʻōlelo ʻia ma ke ʻano he pane piha ʻole, aole he wahi kuai. He pā kiʻekiʻe kēlā, a ʻo ia ka mea e pono ai ka papa noiʻi.
Kaʻina aʻe: E noʻonoʻo i kā mākou mau palapala koi a noi i kahi pepa kikoʻī ma mua o kāu pōʻai hōʻoia e hiki mai ana.
Hōʻike: Hoʻopuka ʻo MOL Changes ma ke ʻano he mea kūʻai peptide, no laila e mālama i kēia loiloi ma ke ʻano hoʻokahi hiʻohiʻona i loko o kahi mākeke e komo ai.

